By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Antiarrhythmic > Dronedarone

Dronedarone

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
4 Min Read
SHARE
3 min read|577 words

Dronedarone Drug Profile

What is Dronedarone?

Dronedarone is a class III antiarrhythmic medication used to treat certain types of irregular heart rhythms. It belongs to the benzofuran class of antiarrhythmic drugs and is chemically related to amiodarone but with a different safety profile. Dronedarone is primarily prescribed to help maintain normal heart rhythm in patients with atrial fibrillation or atrial flutter who have returned to normal rhythm.

Uses

  • Atrial fibrillation maintenance: Helps prevent the recurrence of atrial fibrillation in patients who have been successfully converted to normal heart rhythm
  • Atrial flutter treatment: Used to maintain normal rhythm in patients with a history of atrial flutter
  • Cardiovascular hospitalization reduction: May help reduce the risk of cardiovascular-related hospitalizations in certain patients with atrial fibrillation
  • Heart rate control: Can help control heart rate in patients with paroxysmal atrial fibrillation

How it works

Dronedarone works by blocking multiple ion channels in heart muscle cells, including potassium, sodium, and calcium channels. This multi-channel blocking action helps stabilize the electrical activity of the heart and prevents the abnormal electrical signals that cause irregular heart rhythms. Unlike some other antiarrhythmic drugs, dronedarone also has mild beta-blocking and calcium channel blocking properties, which contribute to its effectiveness in maintaining normal heart rhythm.

Side effects

Common side effects:

  • Diarrhea
  • Nausea and vomiting
  • Abdominal pain
  • Fatigue and weakness
  • Skin rash
  • Bradycardia (slow heart rate)
  • QT prolongation on ECG
  • Increased serum creatinine levels

Serious side effects to watch for:

Submit Your Paper
GMJ_Submit_Banner
  • Severe liver injury or hepatotoxicity
  • Lung toxicity (pulmonary fibrosis)
  • Heart failure worsening
  • Severe bradycardia or heart block
  • New or worsening arrhythmias

Warnings and precautions

  • Heart failure contraindication: Dronedarone should not be used in patients with symptomatic heart failure or recent heart failure hospitalization, as it may increase mortality risk
  • Permanent atrial fibrillation: Not recommended for patients with permanent atrial fibrillation who cannot be converted to normal rhythm
  • Liver monitoring required: Regular liver function tests are necessary due to risk of hepatotoxicity; patients with severe liver impairment should avoid this medication
  • Pregnancy and nursing: Should be avoided during pregnancy and breastfeeding unless benefits clearly outweigh risks
  • Kidney function: May cause increases in serum creatinine; kidney function should be monitored regularly during treatment

Interactions

  • Digoxin: Dronedarone increases digoxin levels significantly, requiring dose reduction and careful monitoring
  • Warfarin and other anticoagulants: May increase bleeding risk by affecting anticoagulant metabolism
  • Statins: Can increase statin levels, potentially leading to muscle toxicity
  • CYP3A4 inhibitors (ketoconazole, clarithromycin): Increase dronedarone levels and toxicity risk
  • Calcium channel blockers: May cause excessive heart rate slowing when used together
  • Beta-blockers: Combined use may lead to severe bradycardia
  • Grapefruit juice: Should be avoided as it can increase drug levels unpredictably
  • St. John’s Wort: May reduce dronedarone effectiveness by increasing its metabolism

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dosage of dronedarone is 400 mg taken twice daily with morning and evening meals. The medication should always be taken with food to improve absorption and reduce gastrointestinal side effects. Dosage adjustments may be necessary in patients with kidney or liver problems, and some patients may require lower doses based on their response to treatment and tolerance of side effects. Healthcare providers will determine the appropriate dosage based on individual patient factors, including other medications, kidney and liver function, and overall health status.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Dronedarone." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/dronedarone/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Multi-cancer blood tests identify missed cancers in 20% of symptomatic patients, Lancet study finds

New blood test technology could help identify one in five cancers that…

UK Approves 47 New Pharmaceutical Manufacturing and Wholesale Dealer Licences in Latest MHRA Review

UK's MHRA has granted 47 new pharmaceutical manufacturing and wholesale dealer licences…

Eric Edwards, Pioneer of UK Kidney Transplantation, Dies

Eric Edwards, the pioneering British urologist who performed the first cadaver kidney…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Flecainide

By
Prof. Giorgi Pkhakadze
02/06/2026

Amiodarone

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up